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RESTORE: an exploratory trial of an online
intervention to enhance self-efficacy to manage
problems associated with cancer-related fatigue
following primary cancer treatment: study
protocol for a randomized controlled trial
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Abstract
Background: There are over 25 million people worldwide living with or beyond cancer and this number is
increasing. Cancer survivors face a range of problems following primary treatment. One of the most frequently
reported and distressing symptoms experienced by cancer survivors is fatigue. There is growing support for
survivors who are experiencing problems after cancer treatment to engage in supported self-management. To date
there is some evidence of effective interventions to manage fatigue in this population; however, to our knowledge
there are no online resources that draw on this information to support self-management of fatigue. This paper
describes the protocol for an exploratory randomized controlled trial of an online intervention to support
self-management of cancer-related fatigue after primary cancer treatment.
Methods/design: This is a parallel-group two-armed (1:1) exploratory randomized controlled trial including 125
cancer survivors experiencing fatigue (scoring ≥4 on a unidimensional 11-point numeric rating scale for fatigue
intensity) within five years of primary treatment completion with curative intent. Participants will be recruited from
13 NHS Trusts across the UK and randomized to either the online intervention (RESTORE), or a leaflet comparator
(Macmillan Cancer Backup, Coping with Fatigue). The primary outcome is a change in Perceived Self-Efficacy for
Fatigue Self-Management (as measured by the Perceived Self-Efficacy for Fatigue Self-Management Instrument).
Secondary outcomes include impact on perception and experience of fatigue (measured by the Brief Fatigue
Inventory), and quality of life (measured by the Functional Assessment of Cancer Therapy - General and the
Personal Wellbeing Index). Outcome measures will be collected at baseline, 6 weeks (completion of intervention),
and 3 months. Process evaluation (including telephone interviews with recruiting staff and participants) will
determine acceptability of the intervention and trial processes.
Discussion: Data from this trial will be used to refine the intervention and contribute to the design of an
effectiveness trial. This intervention will be expanded to address other cancer-related problems important to cancer
survivors following primary cancer treatment.
Trial registration: ISRCTN67521059
Keywords: Cancer survivors, Fatigue, Online, Self-efficacy, Self-management
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Background
There are around 25 million people worldwide living
with or beyond cancer [1], and this number is increas-
ing. With improvements in early diagnosis and treat-
ments, patients are also living longer after cancer and
cancer is beginning to be viewed as a long-term condi-
tion [2]. It is, therefore, of growing importance that the
needs of this population are identified and effective in-
terventions developed to resolve or support management
of cancer-related problems.
The amount of evidence of the range and prevalence of
problems faced by cancer survivors after completion of
treatment is increasing and we know that cancer-related
fatigue (CRF) is a frequently reported and distressing
symptom [3,4], which can persist for a number of years
after completion of treatments [5,6]. The exact prevalence
of fatigue is unknown and appears to vary by tumour type,
treatments received and time since diagnosis. However, it
is generally accepted that around one-third of people
will experience fatigue within the first year following treat-
ment [7,8], and some studies report significantly higher
rates [9,10].
Despite the frequency and debilitating effect of CRF,
the evidence for pharmacological treatment is sparse
[11]. A meta-analysis [12] and Cochrane review [13] sug-
gest that physical activity may improve fatigue; however,
the type, duration and intensity of the exercise that
might be of benefit are not yet known. There is also
some support for the use of cognitive behavioural ther-
apy [14] and psychosocial support [15]; however, there
has been a call for the development of further non-
pharmacological interventions to help patients manage
this symptom [11].
The importance of people taking an active role in man-
aging long-term health conditions is increasingly recog-
nized. It has been reported that this can increase a person’s
self-efficacy, which is in turn associated with improved
quality of life [16]. There is also evidence that self-care be-
haviours improve physical and psychological symptoms
[17]. Our own research indicates that a key component of
self-management for cancer survivors involves the rebuild-
ing of confidence after cancer treatment [18], and that this
confidence is amenable to change [19]. An emphasis on
supported self-management strategies is important from
the perspective of health service planners and policy
makers because of the ever-increasing number of patients
living with long-term consequences of cancer and associ-
ated economic costs. Indeed, in England, the National Can-
cer Survivorship Initiative have highlighted supported
self-management as one of their key areas for development,
and the National Coalition for Cancer Survivorship (United
States) and the Australian Cancer Survivorship Centre have
been established to promote research and development of
services for people living with and beyond cancer.
There is mounting evidence for the efficacy of online in-
terventions in the management of physical symptoms such
as pain [20]. Online interventions have the advantage of
being widely available to those with internet access (83%
of the population of Great Britain [21]) and have been
found to be cost-effective [22]. With an increasing propor-
tion of older adults having access to the internet, there has
also been an emergence of online interventions for this
population. A recent review by Aalbers et al. [23] con-
cluded that complex online interventions in the over 50s,
designed to promote health behaviour change, were
effective.
The development of RESTORE, an online intervention
designed to increase self-efficacy to manage CRF, followed
the recommendations of the Medical Research Council
framework for developing and evaluating complex inter-
ventions [24]. It was informed by the conceptual frame-
work of self-management after cancer treatment previously
described by Foster et al. [25] and is underpinned by the
principles of self-efficacy theory [26]. Bandura proposes
that there are four sources of self-efficacy: performance ac-
complishment, verbal persuasion, vicarious experiences
and physiological states. The RESTORE online interven-
tion therefore includes components designed to enhance
self-efficacy through these sources. The development of
RESTORE is described elsewhere [27].
This paper describes the protocol of the RESTORE ex-
ploratory randomized controlled trial (RCT) and is writ-
ten following CONSORT guidelines [28] and informed
by SPIRIT guidance [29] for clinical trials. The aim of
this study is to test the value (proof of concept) of this
intervention and determine whether its use increases
self-efficacy to self-manage CRF following completion of
primary cancer treatment.
Methods
Design
This is an exploratory, parallel-group RCT and has been
registered with the International Standard Randomized
Controlled Trial Number Register (ISRCTN67521059).
Participants will be randomized in a 1:1 ratio to receive
either the RESTORE online intervention, or a leaflet com-
parator developed by Macmillan Cancer Backup, Coping
with Fatigue [30]. Participants are randomized in blocks of
four, clustered by NHS Trust. An independent statistician
wrote a program using the statistical software R to gener-
ate a sequence of numbers for each NHS Trust. It was not
possible to blind the coordinating research team to group
allocation and the nature of the trial is such that blinding
to patients could not be achieved. Data analysts will be
blinded to group allocation when examining differences
between groups.
This study has received ethical approval from the
NRES Committee South Central – Oxford A, and
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research governance approval from the University Hos-
pital Southampton NHS Foundation Trust, REF RHM
CAN0875. This study has also been adopted by the UK
Cancer Research Network Portfolio (ID 12769), which
provides network resources, including Research Nurse
and Clinical Trial Officer support for recruitment.
Setting and participants
Participants will be recruited from 13 NHS Trusts across
the UK (including sites in England, Scotland, Wales and
Northern Ireland). We aim to recruit 125 patients who
have completed primary treatment with curative intent
for non-metastatic cancer within the last 5 years. Re-
cruitment will take place between September 2012 and
June 2013.
Participants are eligible for the study if they (1) are over
18 years of age, (2) are experiencing fatigue defined as
scoring ≥4 on a unidimensional 11-point numeric rate
scale for fatigue as suggested by the National Comprehen-
sive Cancer Network [31], (3) are able to complete written
records in English, (4) have or are willing to create an
email account and have access to the internet, (5) have
completed primary treatment for invasive cancer (patients
are eligible for the study if they are receiving monoclonal
antibodies or endocrine treatment as maintenance ther-
apy). Patients will be excluded if (1) in the opinion of a
relevant clinician they are unable to give informed con-
sent, (2) have a previously diagnosed mental health condi-
tion that is likely to be exacerbated by participation in the
intervention, (3) are too ill to engage in the intervention
(determined by a member of the patient’s direct clinical
care team).
Patients will be referred by their direct care team at an
end-of-treatment appointment or during follow-up
clinics to the hospital research team (for example, re-
search nurses and clinical trial officers), who will screen
patients for inclusion in the study. Screening will involve
a face-to-face discussion with a member of the team.
The study will be explained and patient status docu-
mented. Possible outcomes are (1) eligible and willing to
participate, (2) eligible and unwilling to participate, and
(3) ineligible. Wherever possible, the reason for declin-
ing participation and ineligibility will be recorded.
Eligible and willing patients will be given a letter of invi-
tation, patient information sheet, reply slip and Freepost
envelope. Patients who, after reading the documentation,
are happy to take part will be asked to complete the reply
slip and return it to the coordinating research team at the
University of Southampton. A member of the coordinating
research team will then contact the patient and discuss
the study, answering any questions. Patients will then be
sent an email including the website address for the RE-
STORE intervention and a unique study ID number. Pa-
tients register with their email, chosen unique password
and study ID number and complete the online consent
form and baseline assessment. A member of the coordin-
ating research team then determines group allocation
from the randomized list and an email is sent to partici-
pants notifying them of their group allocation. See Figure 1
for patient flow through the trial.
The intervention
The RESTORE online intervention was developed using
LifeGuide, open source software [32].
The purpose of this intervention is to increase partici-
pant’s self-efficacy to manage CRF. Table 1 summarizes
the intervention and the components’ association with
self-efficacy theory. Briefly, patients have six weeks to
complete the five sessions of RESTORE. Patients are
presented with sessions one and two (which are compul-
sory) at weekly intervals and can then choose from ses-
sions three to five for the following three weeks. For
example, a participant may choose to visit the same ses-
sion three times, or visit each session once. It is
expected (based on development work) that each session
will take approximately 30 minutes to complete, depend-
ing on the amount of time spent engaging in the sug-
gested activities.
The Macmillan Cancer Backup leaflet, Coping with
Fatigue informed the content of the RESTORE sessions.
Information and components of the intervention were
also informed by the available evidence of fatigue man-
agement in cancer survivors. For example participants
are encouraged to monitor activity patterns and engage
in regular physical activity [12,13]. In addition, session
four (managing thoughts and feelings) draws on the
principles of cognitive behavioural therapy [14]. An ex-
pert design team supported the development of the
RESTORE sessions.
Activities are available throughout RESTORE. These
include a fatigue diary that can be downloaded from the
website as a means of monitoring fatigue, in addition to
completing a single-item assessment of fatigue during
each session. Patient stories (as written text and video
clips) are used throughout to provide examples of how
people affected by CRF have managed the challenges
faced. Automated tailored feedback based on goal-
related progress and change in fatigue levels from the
previous week are included throughout and there are
links to useful resources such as mindfulness and relax-
ation training, and where to access information regard-
ing financial support. ‘Take a break’ buttons are available
during each session, allowing participants to rest if
necessary.
During the trial, patients will receive automated emails
encouraging them to complete the next session if they
have not done so within seven days. Similar emails will
be sent to prompt completion of outcomes measures.
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Comparator group
The leaflet Coping with Fatigue produced by Macmillan
Cancer Backup will be sent to those in the comparator
group. This information leaflet on managing CRF is
widely available in the UK through local information ser-
vices and used by clinical teams. Participants in the
comparator group will be given access to the RESTORE
online intervention once all outcomes measures have
been completed.
Assessments
During screening, the participant’s date of birth, sex and
cancer type will be recorded to allow analysis of factors
influencing uptake.
Baseline assessment (T0) will be completed online im-
mediately after participants consent to the study and
prior to randomization. Demographic information will
include age, sex, ethnicity, marital status, educational
status, accommodation type and postcode. Clinical infor-
mation will also be abstracted from patients’ clinical re-
cords by a member of their hospital research team. This
will include information on cancer diagnosis (date, type
and stage) and treatments received.
The primary outcome measure is the Perceived Self-
Efficacy for Fatigue Self-Management Instrument (PSEFSM)
[33]. The instrument includes six items and respondents are
asked to report their degree of self-efficacy in performing
various tasks on an eleven-point scale. This measure has
been shown to have good reliability (Cronbach’s coefficient
αof 0.92), construct validity and generalizability [33].
A number of secondary outcome measures will be
also assessed.
Figure 1 Flow of patients through the trial.
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Self-efficacy for managing chronic disease will be mea-
sured by the Self-Efficacy for Managing Chronic Disease
6-item Scale [34]. This scale has response options from
1 to 10 (with 10 being most confident) for six items. Re-
spondents are asked to rate their confidence in
performing various activities. The scale has good internal
validity and has been used in cancer populations [35].
Quality of life will be measured by the Functional As-
sessment of Cancer Therapy - General (FACT-G) [36].
This is a 27-item questionnaire consisting of four sub-
scales: physical wellbeing (seven items), social wellbeing
(seven items), emotional wellbeing (six items) and func-
tional wellbeing (seven items). Respondents indicate
how true each statement was for them during the previ-
ous seven days on a five-point Likert scale. Higher
scores indicate higher quality of life. This measure has
proven validity and reliability [36]. The Personal
Wellbeing Index (PWI) will also be used to measure
quality of life. This index includes seven items, which
deconstruct the global question, ‘How satisfied are you
with your life as a whole?’ and has been found to have
good reliability (Cronbach’s α 0.70 to 0.85) [37]. Re-
sponse options are 0 to 10, with higher scores denoting
higher satisfaction with life.
Depression will be assessed using the Patient Health
Questionnaire (PHQ-9). This is a nine-item scale
consisting of two components; one assesses symptoms
and functional impairment, the other assesses severity.
This tool is based on the diagnostic criteria for depres-
sive disorder. This is a reliable and valid measure of de-
pression [38] and has been used extensively, including
among cancer populations [39].
Fatigue will be assessed using the Brief Fatigue Inven-
tory. This is a nine-item scale. Items one to three assess
current, usual and worst levels of fatigue (during the
previous 24 hours). Items four to nine examine the ex-
tent to which fatigue interferes with everyday life, such
as mood, relationships and enjoyment. This scale has
been used in samples of cancer survivors and has been
shown to have good validity and reliability (Cronbach’s α
0.95 to 0.96 [40].
For economic evaluation, items assessing health service
use, caring responsibilities and improvements from a pa-
tient perspective will also be included. The objective of the
economic analysis is to identify the costs (and cost sav-
ings) associated with RESTORE compared with the leaflet
comparator. The analysis will take the perspective of the
health and social care sectors, including third-sector orga-
nizations (for example, hospice care). Patients’ use of these
resources will be collected by way of a bespoke patient
questionnaire. The resources associated with provision
and implementation of RESTORE will be included in the
Table 1 Intervention content and association with self-efficacy theory
RESTORE sessions Content Mandatory/
not mandatory
Self-efficacy
theory construct
Session 1: introduction Defines CRF, possible causes and effects, and outlines purpose
of the intervention
Mandatory Not applicable
Session 2: goal setting Introduces the concept of goal setting and planning; ‘SMART’
(specific, measurable, attainable, relevant, time-bound)
goals are described
Mandatory Performance accomplishments
and verbal persuasion
Session 3: diet, sleep,
exercise, home life and work
Describes how CRF may impact on these aspects of everyday
life and how effective goal setting can help manage
this interference
Not mandatory Performance accomplishments
and verbal persuasion
Session 4: thoughts
and feelings
Psychological aspects of CRF and how these can
be managed, including through goal setting
Not
mandatory
Performance accomplishments
and verbal persuasion
Session 5: talking to others Describes the difficulties of talking to others (friends, family,
colleagues, health professionals), and some strategies
on how to manage this, including through goal setting
Not mandatory Performance accomplishments
and verbal persuasion
Activities suggested throughout
Patient stories Extracts from people affected by cancer and who have experienced
fatigue; sharing their experiences and methods of self-management,
written text and video clips
Not mandatory Vicarious experiences
Self-monitoring The use of a fatigue diary to monitor fatigue and understand its
pattern
Not mandatory Physiological experiences
Monitoring fatigue each time a participant logs into RESTORE Mandatory
Feedback Personal feedback on success of goal setting, planning and fatigue
level
Mandatory Performance accomplishments
and verbal persuasion
Web links Web links to useful resources Not mandatory Not applicable
Take a break buttons Provided throughout to allow participants to rest during sessions
if required
Not
mandatory
Not applicable
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analysis. These will be based on routine data, such as ad-
ministrative records, as well as a detailed description of
the implementation and the development process of the
intervention. Unit costs for health service resources will
be obtained from national sources such as the Personal
Social Services Research Unit (PSSRU), the British Na-
tional Formulary and NHS Reference cost database.
Where national unit costs are not available, the finance
departments of trusts participating in the study will be
asked to provide local cost data. The mean of these costs
will be used as the unit cost estimate in the analysis. The
results will be presented alongside the primary and sec-
ondary outcomes as a cost consequence analysis.
All primary and secondary outcome measures will be
assessed at baseline (T0), six weeks (T1; completion of
intervention) and three months (T2; end of study). T2
will act as our primary endpoint.
This is an exploratory trial and therefore a mixed-
methods process evaluation will evaluate the feasibility
and acceptability of the intervention. Quantitatively, ad-
herence to the intervention (that is, number of sessions
completed) will be examined, as will completion rates of
questionnaire items at all three time points. Recruitment
rates will be calculated based on the number of eligible
patients approached versus those who consent to take
part in the trial. The proportion of ineligible patients will
also be described and reasons for ineligibility docu-
mented. Eligible patients who decline participation will
also be asked to volunteer a reason for this. Acceptability
of the intervention will be inferred by attrition rates.
Additionally, semistructured telephone interviews with
participants will explore feasibility and acceptability in
more depth. We will recruit a maximum variation sam-
ple of men (n ≈ 15) and women (n ≈ 15) where variation
will be by (a) cancer type and time since treatment com-
pletion, and (b) compliance with the intervention. The
interview schedule will be structured to identify, describe
and explain the impact of CRF on participants, the per-
ceived acceptability of online interventions and the value
of RESTORE to them (for example, improved confi-
dence, reduced interference of CRF in daily life), and fac-
tors that promote or inhibit the integration of RESTORE
into everyday life. Telephone interviews will be tran-
scribed and analyzed using directed content analysis
[41]. Analysis will be informed by Normalization Process
Theory [42,43].
Sample size
We aim to recruit 125 patients to this trial. Currently,
there is no definitive guidance on the size of exploratory
trials. We feel that this is an achievable sample size based
on the resources available and is adequate to allow for
a relatively high attrition rate while still leaving a reason-
able final sample. Also, the primary outcome measure
(PSEFSM) could not be used to determine a power calcu-
lation as the measure is new and insufficient data are
available. A definitive sample size for a large scale RCT
will be determined from results of this trial.
Analysis
The principal analysis will involve fitting between group, re-
peated measures models with two levels of treatment vari-
able (intervention group, leaflet group) and three time
points (T0, T1, T2) to the primary and secondary outcome
measures. Distribution of the outcomes will be inspected to
identify the appropriate form of the response variables for
the modelling. Model assumptions will be checked and out-
comes will be transformed where there is strong evidence
of non-normality, for example by taking logs, dichotomiz-
ing or categorizing into three or more ordered categories.
The appropriate mixed effects, repeated measures model
(normal, binary or ordinal) will be fitted with random coef-
ficients on the time points and a random intercept for trust
to control for within-subject and within-Trust correlations.
All data will be analyzed blind to treatment condition and
intention to treat analysis will be undertaken. Auxiliary ana-
lyses will assess the interaction of potential modifiers (for
example, age, sex, socio-economic status, cancer treatment
received, cancer type) with treatment in the models.
Change over time of the primary and all secondary out-
come measures will be examined.
Study funding
This study is funded by Macmillan Cancer Support as
part of a programme of research.
Serious adverse events reporting and monitoring
It is not anticipated that there will be any risk to partici-
pants, therefore only serious adverse events will be
reported. Any serious adverse events deemed to be re-
lated to the intervention or due to participation in the
study will be reported to the chief investigator within 24
hours of the team learning of its occurrence.
Discussion
The RESTORE resource provides a novel intervention and
this trial will explore its feasibility as a self-management
tool to support people living with CRF following primary
cancer treatment. To the best of our knowledge this is the
first online intervention designed to increase self-efficacy
in managing CRF in patients who have completed primary
cancer treatment. As the number of people living with and
beyond cancer continues to increase, there will be a grow-
ing need for evidence-based support tools.
The results of this study will determine whether RE-
STORE is acceptable to people living with and beyond
cancer, and whether recruitment into a full-scale trial is
both warranted and feasible.
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This study has strengths and weaknesses. We have only
included patients with curative disease and who are within
five years of treatment completion. The intervention is
also only available in English. However, the exploratory
nature of the study will permit refinement of the interven-
tion and consideration of optimal study design for a larger
trial. The study will also provide important information as
to whether this typically older population of cancer survi-
vors is accepting of an online based intervention, and if
the intervention is feasible and acceptable. It is hoped that
this intervention will be expanded in the future to support
the management of other cancer-related problems.
Trial status
Recruiting. Recruitment closes June 2013.
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